NCT07225439
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07225439
Title Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Paolo Caimi, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.